ID

41154

Description

A Phase II Trial of Induction Chemotherapy With ND-420, Cisplatin and Fluorouracil Followed by Surgery in the Treatment of Patients With Localized Squamous Cell Carcinoma of the Esophagus; ODM derived from: https://clinicaltrials.gov/show/NCT02017600

Link

https://clinicaltrials.gov/show/NCT02017600

Keywords

  1. 7/2/20 7/2/20 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

July 2, 2020

DOI

To request one please log in.

License

Creative Commons BY 4.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Localized Squamous Cell Carcinoma of the Esophagus NCT02017600

Eligibility Localized Squamous Cell Carcinoma of the Esophagus NCT02017600

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
patients must have been histologically proven esophageal carcinoma (squamous cell carcinoma).
Description

Squamous cell carcinoma of esophagus

Data type

boolean

Alias
UMLS CUI [1]
C0279626
the tumor had to be locally advanced (stage t2-3/n0, t1-3/n+, if technically resectable with curative intent).
Description

Locally Advanced Malignant Neoplasm TNM clinical staging

Data type

boolean

Alias
UMLS CUI [1,1]
C0677984
UMLS CUI [1,2]
C3258246
patients must be 20 years of age.
Description

Age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
patients must have an ecog performance status score 2.
Description

ECOG performance status

Data type

boolean

Alias
UMLS CUI [1]
C1520224
patients must have a life expectancy of at least 12 weeks.
Description

Life Expectancy

Data type

boolean

Alias
UMLS CUI [1]
C0023671
patients must be accessible for treatment and follow-up at least for one year.
Description

Patient Available Therapeutic procedure | Patients Available Follow-up

Data type

boolean

Alias
UMLS CUI [1,1]
C0030705
UMLS CUI [1,2]
C0470187
UMLS CUI [1,3]
C0087111
UMLS CUI [2,1]
C0030705
UMLS CUI [2,2]
C0470187
UMLS CUI [2,3]
C3274571
patients must sign the informed consent form.
Description

Informed Consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
patient must have:hemoglobin level 9 g/dl; neutrophil count 1,500/mm3; platelets count 100,000/mm3; serum bilirubin level 1.0 uln; serum transaminase (got, gpt) levels 2.0 uln; serum alkaline phosphatase levels 2.0 uln; serum creatinine level 1.5 mg/dl or creatinine clearance rate(crcl)60 ml/min for the institution (calculated by the cockcroft- gault equation).
Description

Hemoglobin measurement | Neutrophil count | Platelet Count measurement | Serum total bilirubin measurement | Aspartate aminotransferase measurement | Alanine aminotransferase measurement | Alkaline phosphatase measurement | Creatinine measurement, serum | Estimation of creatinine clearance by Cockcroft-Gault formula

Data type

boolean

Alias
UMLS CUI [1]
C0518015
UMLS CUI [2]
C0200633
UMLS CUI [3]
C0032181
UMLS CUI [4]
C1278039
UMLS CUI [5]
C0201899
UMLS CUI [6]
C0201836
UMLS CUI [7]
C0201850
UMLS CUI [8]
C0201976
UMLS CUI [9]
C2711451
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
patient who are receiving or had received concurrent radiotherapy, chemotherapy or other anticancer treatment for esophageal carcinoma.
Description

Therapeutic radiology procedure Esophageal carcinoma | Chemotherapy Esophageal carcinoma | Cancer treatment Esophageal carcinoma

Data type

boolean

Alias
UMLS CUI [1,1]
C1522449
UMLS CUI [1,2]
C0152018
UMLS CUI [2,1]
C0392920
UMLS CUI [2,2]
C0152018
UMLS CUI [3,1]
C0920425
UMLS CUI [3,2]
C0152018
patients with known history of severe hypersensitivity reactions to any medicine or to drugs formulated with polysorbate 80.
Description

Severe allergy Pharmaceutical Preparations | Severe allergy Polysorbate 80

Data type

boolean

Alias
UMLS CUI [1,1]
C2945656
UMLS CUI [1,2]
C0013227
UMLS CUI [2,1]
C2945656
UMLS CUI [2,2]
C0032601
major surgery within two weeks prior to entering the study, excluding port-a insertion or feeding jejunostomy surgery.
Description

Major surgery | Exception Port-A-Cath | Exception Jejunostomy feeding

Data type

boolean

Alias
UMLS CUI [1]
C0679637
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C3495140
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0192715
patients with cns metastasis, including clinical suspicion.
Description

CNS metastases | Suspicion CNS metastases

Data type

boolean

Alias
UMLS CUI [1]
C0686377
UMLS CUI [2,1]
C0242114
UMLS CUI [2,2]
C0686377
patients with clinically detectable peripheral neuropathy 2 on the ctc criteria.
Description

Peripheral Neuropathy CTCAE Grades

Data type

boolean

Alias
UMLS CUI [1,1]
C0031117
UMLS CUI [1,2]
C1516728
mental statuses of patients are not fit for clinical trial.
Description

Mental state unfit Clinical Trial

Data type

boolean

Alias
UMLS CUI [1,1]
C0278060
UMLS CUI [1,2]
C3841806
UMLS CUI [1,3]
C0008976
fertile men and women unless using a reliable and appropriate contraceptive method.
Description

Females & males of reproductive potential | Exception Contraceptive methods

Data type

boolean

Alias
UMLS CUI [1]
C4034483
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0700589
patients with pregnancy or lactating, women considering pregnancy, possible pregnancy that without using effective contraception.
Description

Pregnancy | Breast Feeding | Gender considering Pregnancy | Possible pregnancy | Contraceptive methods Absent

Data type

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
UMLS CUI [3,1]
C0079399
UMLS CUI [3,2]
C0750591
UMLS CUI [3,3]
C0032961
UMLS CUI [4]
C0425965
UMLS CUI [5,1]
C0700589
UMLS CUI [5,2]
C0332197
patients who have serious concomitant illness that might be aggravated by chemotherapy, as below included:active cardiac disease (e.g. congestive heart failure, angina, arrhythmia, acute myocardial disease or other types of heart disease requiring treatment) within 6 months period preceding entry into the study; uncontrolled infection (e.g. active infection that uncontrolled for 2 weeks under antibiotic therapy); retention of body fluid (e.g. pleural effusion, ascites, pericardial effusion, and edema needing treatment); history of other than esophageal cancer, except curatively treated non-melanoma skin cancer or in situ carcinoma of the esophagus; and other conditions which will be judged by physician's discretion.
Description

Comorbidity Serious | Heart Disease | Congestive heart failure | Angina Pectoris | Cardiac Arrhythmia | Cardiomyopathy | Communicable Disease Uncontrolled | Body fluid retention | Pleural effusion | Ascites | Pericardial effusion | Edema Treatment required for | Cancer Other | Exception Curative treatment Skin carcinoma | Exception Curative treatment Carcinoma in situ of esophagus

Data type

boolean

Alias
UMLS CUI [1,1]
C0009488
UMLS CUI [1,2]
C0205404
UMLS CUI [2]
C0018799
UMLS CUI [3]
C0018802
UMLS CUI [4]
C0002962
UMLS CUI [5]
C0003811
UMLS CUI [6]
C0878544
UMLS CUI [7,1]
C0009450
UMLS CUI [7,2]
C0205318
UMLS CUI [8]
C0268000
UMLS CUI [9]
C0032227
UMLS CUI [10]
C0003962
UMLS CUI [11]
C0031039
UMLS CUI [12,1]
C0013604
UMLS CUI [12,2]
C0332121
UMLS CUI [13]
C1707251
UMLS CUI [14,1]
C1705847
UMLS CUI [14,2]
C1273390
UMLS CUI [14,3]
C0699893
UMLS CUI [15,1]
C1705847
UMLS CUI [15,2]
C1273390
UMLS CUI [15,3]
C0154059

Similar models

Eligibility Localized Squamous Cell Carcinoma of the Esophagus NCT02017600

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Squamous cell carcinoma of esophagus
Item
patients must have been histologically proven esophageal carcinoma (squamous cell carcinoma).
boolean
C0279626 (UMLS CUI [1])
Locally Advanced Malignant Neoplasm TNM clinical staging
Item
the tumor had to be locally advanced (stage t2-3/n0, t1-3/n+, if technically resectable with curative intent).
boolean
C0677984 (UMLS CUI [1,1])
C3258246 (UMLS CUI [1,2])
Age
Item
patients must be 20 years of age.
boolean
C0001779 (UMLS CUI [1])
ECOG performance status
Item
patients must have an ecog performance status score 2.
boolean
C1520224 (UMLS CUI [1])
Life Expectancy
Item
patients must have a life expectancy of at least 12 weeks.
boolean
C0023671 (UMLS CUI [1])
Patient Available Therapeutic procedure | Patients Available Follow-up
Item
patients must be accessible for treatment and follow-up at least for one year.
boolean
C0030705 (UMLS CUI [1,1])
C0470187 (UMLS CUI [1,2])
C0087111 (UMLS CUI [1,3])
C0030705 (UMLS CUI [2,1])
C0470187 (UMLS CUI [2,2])
C3274571 (UMLS CUI [2,3])
Informed Consent
Item
patients must sign the informed consent form.
boolean
C0021430 (UMLS CUI [1])
Hemoglobin measurement | Neutrophil count | Platelet Count measurement | Serum total bilirubin measurement | Aspartate aminotransferase measurement | Alanine aminotransferase measurement | Alkaline phosphatase measurement | Creatinine measurement, serum | Estimation of creatinine clearance by Cockcroft-Gault formula
Item
patient must have:hemoglobin level 9 g/dl; neutrophil count 1,500/mm3; platelets count 100,000/mm3; serum bilirubin level 1.0 uln; serum transaminase (got, gpt) levels 2.0 uln; serum alkaline phosphatase levels 2.0 uln; serum creatinine level 1.5 mg/dl or creatinine clearance rate(crcl)60 ml/min for the institution (calculated by the cockcroft- gault equation).
boolean
C0518015 (UMLS CUI [1])
C0200633 (UMLS CUI [2])
C0032181 (UMLS CUI [3])
C1278039 (UMLS CUI [4])
C0201899 (UMLS CUI [5])
C0201836 (UMLS CUI [6])
C0201850 (UMLS CUI [7])
C0201976 (UMLS CUI [8])
C2711451 (UMLS CUI [9])
Item Group
C0680251 (UMLS CUI)
Therapeutic radiology procedure Esophageal carcinoma | Chemotherapy Esophageal carcinoma | Cancer treatment Esophageal carcinoma
Item
patient who are receiving or had received concurrent radiotherapy, chemotherapy or other anticancer treatment for esophageal carcinoma.
boolean
C1522449 (UMLS CUI [1,1])
C0152018 (UMLS CUI [1,2])
C0392920 (UMLS CUI [2,1])
C0152018 (UMLS CUI [2,2])
C0920425 (UMLS CUI [3,1])
C0152018 (UMLS CUI [3,2])
Severe allergy Pharmaceutical Preparations | Severe allergy Polysorbate 80
Item
patients with known history of severe hypersensitivity reactions to any medicine or to drugs formulated with polysorbate 80.
boolean
C2945656 (UMLS CUI [1,1])
C0013227 (UMLS CUI [1,2])
C2945656 (UMLS CUI [2,1])
C0032601 (UMLS CUI [2,2])
Major surgery | Exception Port-A-Cath | Exception Jejunostomy feeding
Item
major surgery within two weeks prior to entering the study, excluding port-a insertion or feeding jejunostomy surgery.
boolean
C0679637 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C3495140 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0192715 (UMLS CUI [3,2])
CNS metastases | Suspicion CNS metastases
Item
patients with cns metastasis, including clinical suspicion.
boolean
C0686377 (UMLS CUI [1])
C0242114 (UMLS CUI [2,1])
C0686377 (UMLS CUI [2,2])
Peripheral Neuropathy CTCAE Grades
Item
patients with clinically detectable peripheral neuropathy 2 on the ctc criteria.
boolean
C0031117 (UMLS CUI [1,1])
C1516728 (UMLS CUI [1,2])
Mental state unfit Clinical Trial
Item
mental statuses of patients are not fit for clinical trial.
boolean
C0278060 (UMLS CUI [1,1])
C3841806 (UMLS CUI [1,2])
C0008976 (UMLS CUI [1,3])
Females & males of reproductive potential | Exception Contraceptive methods
Item
fertile men and women unless using a reliable and appropriate contraceptive method.
boolean
C4034483 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0700589 (UMLS CUI [2,2])
Pregnancy | Breast Feeding | Gender considering Pregnancy | Possible pregnancy | Contraceptive methods Absent
Item
patients with pregnancy or lactating, women considering pregnancy, possible pregnancy that without using effective contraception.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0079399 (UMLS CUI [3,1])
C0750591 (UMLS CUI [3,2])
C0032961 (UMLS CUI [3,3])
C0425965 (UMLS CUI [4])
C0700589 (UMLS CUI [5,1])
C0332197 (UMLS CUI [5,2])
Comorbidity Serious | Heart Disease | Congestive heart failure | Angina Pectoris | Cardiac Arrhythmia | Cardiomyopathy | Communicable Disease Uncontrolled | Body fluid retention | Pleural effusion | Ascites | Pericardial effusion | Edema Treatment required for | Cancer Other | Exception Curative treatment Skin carcinoma | Exception Curative treatment Carcinoma in situ of esophagus
Item
patients who have serious concomitant illness that might be aggravated by chemotherapy, as below included:active cardiac disease (e.g. congestive heart failure, angina, arrhythmia, acute myocardial disease or other types of heart disease requiring treatment) within 6 months period preceding entry into the study; uncontrolled infection (e.g. active infection that uncontrolled for 2 weeks under antibiotic therapy); retention of body fluid (e.g. pleural effusion, ascites, pericardial effusion, and edema needing treatment); history of other than esophageal cancer, except curatively treated non-melanoma skin cancer or in situ carcinoma of the esophagus; and other conditions which will be judged by physician's discretion.
boolean
C0009488 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C0018799 (UMLS CUI [2])
C0018802 (UMLS CUI [3])
C0002962 (UMLS CUI [4])
C0003811 (UMLS CUI [5])
C0878544 (UMLS CUI [6])
C0009450 (UMLS CUI [7,1])
C0205318 (UMLS CUI [7,2])
C0268000 (UMLS CUI [8])
C0032227 (UMLS CUI [9])
C0003962 (UMLS CUI [10])
C0031039 (UMLS CUI [11])
C0013604 (UMLS CUI [12,1])
C0332121 (UMLS CUI [12,2])
C1707251 (UMLS CUI [13])
C1705847 (UMLS CUI [14,1])
C1273390 (UMLS CUI [14,2])
C0699893 (UMLS CUI [14,3])
C1705847 (UMLS CUI [15,1])
C1273390 (UMLS CUI [15,2])
C0154059 (UMLS CUI [15,3])

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial